ƒAƒgƒs[«”畆‰Š ‹ãB‘åŠwˆãŠw•””畆‰ÈŠw‹³ŽºTOP‚Ö
ƒXƒeƒƒCƒhŠO—p—Ö@
Œ¤‹†•ª’SŽÒ@‘å–îKO@@@@@@@@@@@@@@
Œ¤‹†‹¦—͎ҁ@“ñ‘º¹Ž÷@¬“c‰ë”ü@’Ѻ—R‹I
‘—§¬ˆçˆã—ÃŒ¤‹†ƒZƒ“ƒ^[“à‰ÈŒnf—Õ”ƒAƒŒƒ‹ƒM[‰È
‘—§¬ˆçˆã—ÃŒ¤‹†ƒZƒ“ƒ^[“à‰ÈŒnf—Õ”ƒAƒŒƒ‹ƒM[‰È
—vŽ| ‚Í‚¶‚ß‚É –Ú“I‚Æ•û–@ Œ‹‰Ê lŽ@ Œ‹˜_ ŽQl•¶Œ£
ƒXƒeƒƒCƒhŠO—p—Ö@•]‰¿•\ˆê——
•]‰¿•\‚ÌŒ©•û
•]‰¿–@‚ÌŒ©•û
ŽQl•¶Œ£
1. Gehring, W. and M. Gloor, Treatment of the atopic dermatitis with a water-in-oil emulsion with or without the addition of hydrocortisone-results of a controlled double-blind randomized study using clinical evaluation and bioengineering methods. . Z Hautkr, 1996. 71: p. 554-60.
2. Sears, H.W., J.W. Bailer, and A. Yeadon, Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis. Clin Ther, 1997. 19(4): p. 710-9.
3. Korting, H.C., et al., Comparative efficacy of hamamelis distillate and hydrocortisone cream in atopic eczema. Eur J Clin Pharmacol, 1995. 48(6): p. 461-5.
4. Stalder, J.F., et al., Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol, 1994. 131(4): p. 536-40.
5. Lupton, E.S., M.M. Abbrecht, and M.L. Brandon, Short-term topical corticosteroid therapy (halcinonide ointment) in the management of atopic dermatitis. Cutis, 1982. 30(5): p. 671-5.
6. Sudilovsky, A., J.G. Muir, and F.C. Bocobo, A comparison of single and multiple applications of halcinonide cream. Int J Dermatol, 1981. 20(9): p. 609-13.
7. Wahlgren, C.F., et al., Evaluation of a new method of assessing pruritus and antipruritic drugs. Skin Pharmacol, 1988. 1(1): p. 3-13.
8. Van Der Meer, J.B., et al., The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic DermatitisStudy Group. Br J Dermatol, 1999. 140(6): p. 1114-21.
9. Sefton, J., J.S. Loder, and A.A. Kyriakopoulos, Clinical evaluation of hydrocortisone valerate 0.2% ointment. Clin Ther, 1984. 6(3): p. 282-93.
10. Brock, W. and S.I. Cullen, Triamcinolone acetonide in flexible collodion for dermatologic therapy. Arch Dermatol, 1967. 96(2): p.
193-4.
11. Maloney, J.M., et al., Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis. Int J Dermatol, 1998. 37(2): p. 142-4.
12. Patzelt-Wenczler, R. and E. Ponce-Poschl, Proof of efficacy of Kamillosan(R) cream in atopic eczema. Eur J Med Res, 2000. 5(4): p. 171-5.
13. Freeman, S., et al., Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis. Australas J Dermatol, 2002. 43(3): p. 186-9.
14. Roth, H.L. and E.P. Brown, Hydrocortisone valerate. Double-blind comparison with two other topical steroids. Cutis, 1978. 21(5): p. 695-8.
15. Bircher, A.J., et al., Stealth triamcinolone acetonide in a phytocosmetic cream. Br J Dermatol, 2002. 146(3): p. 531-2.
16. Lebwohl, M., Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema. Cutis, 1996. 57(2 Suppl): p. 62-8.
17. Lawlor, F., A. Black, and M. Geaves, Prednicarbate 0.25% ointment in the treatment of atopic dermatitis: a vehicle-controlled double-blind study. J Dermatol Treat, 1995. 6: p. 233-5.
18. Breneman, D., et al., Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream. J Drugs Dermatol, 2005. 4(3): p. 330-6.
19. Matheson, R., et al., Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. J Drugs Dermatol, 2008. 7(3): p. 266-71.
20. Hebert, A.A., Desonide foam 0.05%: safety in children as young as 3 months. J Am Acad Dermatol, 2008. 59(2): p. 334-40.
21. Kimball, A.B., et al., Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents. J Am Acad Dermatol, 2008. 59(3): p. 448-54, 454 e1.
22. Hebert, A.A., et al., Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. J Drugs Dermatol, 2007. 6(2): p. 175-81.
23. Eichenfield, L.F. and B.H. Miller, Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age. J Am Acad Dermatol, 2006. 54(4): p. 715-7.
24. Vanderploeg, D.E., Betamethasone dipropionate ointment in the treatment of psoriasis and atopic dermatitis: a double-blind study. South Med J, 1976. 69(7): p. 862-3.
25. Paller, A.S., et al., Fluocinolone acetonide 0.01% in peanut oil: therapy for childhood atopic dermatitis, even in patients who are peanut sensitive. J Am Acad Dermatol, 2003. 48(4): p. 569-77.
26. Pellanda, C., et al., Low-dose triamcinolone acetonide in the phytocosmetic lichtena reduces inflammation in mild to moderate atopic dermatitis. Dermatology, 2005. 211(4): p. 338-40.
27. Lebwohl, M., A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group. Int J Dermatol, 1999. 38(8): p. 604-6.
28. Camacho F, G.B.B., Diaz Perez JL, Aguirre A, Arnau C, Garcia Barbal J, et al., A comparative intraindividual double-blind assay between prednicarbate and fluocortolone in the management of atopic dermatitis. Actas Dermo Sifiliograficas, 1996. 87(1-2): p. 59-63.
29. Bleeker, J., Double-blind comparison between two new topical corticosteroids, halcinonide 0.1% and clobetasol propionate cream 0.05%. Curr Med Res Opin, 1975. 3(4): p. 225-8.
30. Haneke, E., The treatment of atopic dermatitis with methylprednisolone aceponate(mpa), a new topical corticosteroid. J Dermatol Treat, 1992. 3(Suppl 2): p. 13-5.
31. Bagatell FK, B.J., Cohen HJ, Lasser AE, McCormick GE, Rex IH, et al., A multi-center comparison of alclometasone dipropionate cream 0.05% and hydrocortisone cream 1.0% in the treatment of atopic dermatitis. Curr Ther Res Clin Exp, 1983. 33(1): p. 46-52.
32. Gelmetti C, G.R., Del Campo G, Caputo R, Tolerability and efficacy of topical budesonide in the treatment of atopic dermatitis in pediatric age. G Ital Dermatol Venereol, 1994. 129(3): p. XIII-XVII.
33. Majerus, J.P. and J. Reiffers-Mettelock, Sicorten: a synthetic corticosteroid for topical treatment of common dermatoses. J Int Med Res, 1986. 14(1): p. 46-9.
34. Jorizzo, J., et al., Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol, 1995. 33(1): p. 74-7.
35. Leibsohn, E. and F.K. Bagatell, Halcinonide in the treatment of corticosteroid responsive dermatoses. Br J Dermatol, 1974. 90(4): p. 435-40.
36. Fisher, M. and A.P. Kelly, Multicenter trial of fluocinonide in an emollient cream base. Int J Dermatol, 1979. 18(8): p. 660-4.
37. Yasuda, T., Clinical experiences with hydrocortisone 17-butyrate. Dermatologica, 1976. 152 Suppl 1: p. 221-9.
38. Binder, R. and J. McCleary, Comparison of fluocinonide in a double-blind study with betamethasone valerate. Curr Ther Res Clin Exp, 1972. 14(1): p. 35-8.
39. Duke EE, M.S., Aggerwal A, Alclometasone dipropionate in atopic dermatitis: a clinical study. Curr Ther Res Clin Exp, 1983. 33(5): p. 769-74.
40. Rajka, G. and H.L. Verjans, Hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream versus desonide (Apolar) 0.1% ointment in the treatment of patients suffering from atopic dermatitis. J Int Med Res, 1986. 14(2): p. 85-90.
41. Veien, N.K., et al., Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol, 1999. 140(5): p. 882-6.
42. Lassus, A., Clinical comparison of alclometasone dipropionate cream 0.05% with hydrocortisone butyrate cream 0.1% in the treatment of atopic dermatitis in children. J Int Med Res, 1983. 11(5): p. 315-9.
43. el-Hefnawi, H., et al., Double-blind paired comparison clinical trial of halcinonide and hydrocortisone. Cutis, 1978. 22(1): p. 97-9.
44. Bluefarb, S.M., et al., Diflorasone diacetate: vasoconstrictor activity and clinical efficacy of a new topical corticosteroid. J Int Med Res, 1976. 4(6): p. 454-61.
45. Morley, N., L. Fry, and S. Walker, Clinical evaluation of clobetasone butyrate in the treatment of children with atopic eczema, and its effect on plasma corticosteroid levels. Curr Med Res Opin, 1976. 4(3): p. 223-8.
46. Bjornberg, A. and L. Hellgren, [Comparison between 2 steroid dosage forms in psoriasis and eczema]. Z Hautkr, 1975. Suppl 2: p. 13-5.
47. Almeyda, J. and L. Fry, Controlled trial of the treatment of atopic eczema with a urea-hydrocortisone preparation versus betamethasone 17-valerat. Br J Dermatol, 1973. 88(5): p. 493-5.
48. Rampini, E., Methylprenisolone aceponate(MPA)-use and clinical experience in children. J Dermatol Treat, 1992. 3(Suppl 2): p. 27-9.
49. Hoybye S, B.M.S., De Cunha Bang F, Ottevanger V, Veien NK, Continuous and intermittent treatment of atopic dermatitis in adults with momethasone furoate vs. hydrocortisone 17-butyrate. Curr Ther Res Clin Exp, 1991. 50: p. 67-72.
50. Lassus, A., Alclometasone dipropionate cream 0.05% versus clobetasone butyrate cream 0.05%. A controlled clinical comparison in the treatment of atopic dermatitis in children. Int J Dermatol, 1984. 23(8): p. 565-6.
51. Sefton, J. and A.A. Kyriakopoulos, Comparative efficacy of hydrocortisone valerate 0.2 percent ointment in the treatment of atopic dermatitis. Cutis, 1983. 32(1): p. 89-91, 94.
52. Nolting, S., [Treatment with topical corticosteroids in severe or resistant dermatoses]. Derm Beruf Umwelt, 1985. 33(4): p. 140-4.
53. Van DelRey ML, G.M., Azulay RD, Estudo duplo-cego sobre a eficacia e a seguranca do creme de alcometasoma no tratamento de dermatite atopica./ [Double-blind study on the efficacy and safety of alclomethasone cream in the treatment of atopic dermatitis.]. An Bras Dermatol, 1983. 58: p. 177-80.
54. Konzelmann, M. and M. Harms, [Diflorasone diacetate cream compared to betamethasone dipropionate cream in the treatment of eczemas]. Schweiz Rundsch Med Prax, 1983. 72(20): p. 709-11.
55. Harder, F. and T. Rufli, [Therapy of eczema. Once daily use of diflorasone diacetate in comparison to thrice daily use of betamethasone-17-valerate]. Schweiz Rundsch Med Prax, 1983. 72(39): p. 1240-2.
56. Savin, R.C., Betamethasone dipropionate in psoriasis and atopic dermatitis. Conn Med, 1976. 40(1): p. 5-7.
57. Ramelet AA, M.E., Treatment of resistant steroid-responsive dermatoses: a comparison of Diprolene and Neriforte. Clin Trials J, 1982. 19: p. 298-307.
58. Prado de Oliveira, Z., L. Cuce, and M. Arnone, Comparative evaluation of efficacy, tolerability and safety of 0.1% topical monethasone furoate and 0.05% desonide in the treatment of childhood atopic dermatitis. . Anais Brasileiros de dermatologia, 2002. 77(1): p. 25-33.
59. Lebrun-Vignes, B., et al., [Comparative study of efficacy and effect on plasma cortisol levels of micronised desonide cream 0.1 p. 100 versus betamethasone dipropionate cream 0.05 p. 100 In the treatment of childhood atopic dermatitis]. Ann Dermatol Venereol, 2000. 127(6-7): p. 590-5.
60. Almeyda, J. and B.W. Burt, Double blind controlled study of treatment of atopic eczema with a preparation of hydrocortisone in a new drug delivery system versus betamethasone 17-valerate. Br J Dermatol, 1974. 91(5): p. 579-83.
61. Veien NK, H.T., Justesen O, Norholm A, Verjans HL, Hydrocortisone 17-butyrate (Locoid) 0.1% cream versus hydrocortisone (Uniderm) 1% cream in the treatment of children suffering from atopic dermatitis. J Int Med Res, 1984. 12(5): p. 310-3.
62. Wachs, G.N. and H.I. Maibach, Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br J Dermatol, 1976. 95(3): p. 323-8.
63. Hjorth, N., H. Schmidt, and K. Thomsen, Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica, 1985. 4(2): p. 126-31.
64. Wilkinson RD, L.D., Comparative efficacy of betamethasone and either fusidic acid or neomycin in infected or potentially infected eczema. . Curr Ther Res., 1985. 38: p. 177-182.
65. Meenan, F.O., A double-blind comparative study to compare the efficacy of Locoid C with Tri-Adcortyl in children with infected eczema. Br J Clin Pract, 1988. 42(5): p. 200-2.
66. Zienicke, H., Topical glucocorticoids and anti-infectives: a rational combination? Curr Probl Dermatol, 1993. 21: p. 186-91.
67. Ramsay CA, S.J., Gilbert M, Gidon M, Kidson P, The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. J Eur Acad Dermatol Venereol., 1996. 7(suppl): p. S15-S22.
68. Ravenscroft, J.C., et al., Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in atopic eczema. Br J Dermatol, 2003. 148(5): p. 1010-7.
69. Gong, J.Q., et al., Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol, 2006. 155(4): p. 680-7.
70. Larsen, F.S., et al., An efficient new formulation of fusidic acid and betamethasone 17-valerate (fucicort lipid cream) for treatment of clinically infected atopic dermatitis. Acta Derm Venereol, 2007. 87(1): p. 62-8.
71. Schuttelaar, M.L. and P.J. Coenraads, A randomized, double-blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide in the treatment of moderate to severe atopic dermatitis. J Eur Acad Dermatol Venereol, 2008. 22(9): p. 1076-82.
72. Anonymous., Treatment of eczemas and infected eczemas. Br J Clin Pract., 1967. 21(10): p. 505-507.
73. Hanifin JM, H.A., Mays SR, Paller AS, Sherertz EF, Wagner AM, et al., Effects of a low-potency corticosteroid lotion plus a moisturizing regimen in the treatment of atopic dermatitis. Curr Ther Res Clin Exp, 1998. 59(4): p. 227-233.
74. Draelos, Z.D., The effect of ceramide-containing skin care products on eczema resolution duration. Cutis, 2008. 81(1): p. 87-91.
75. Msika, P., et al., New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement. Pediatr Dermatol, 2008. 25(6): p. 606-12.
76. Szczepanowska, J., A. Reich, and J.C. Szepietowski, Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol, 2008. 19(7): p. 614-8.
77. Sandstrom Falk, M.H., et al., Treatment of atopic dermatitis with 1% hydrocortisone and 25% pentane-1,5-diol: effect on Staphylococcus aureus. Acta Derm Venereol, 2006. 86(4): p. 372-3.
78. Cato, A., et al., Azone enhances clinical effectiveness of an optimized formulation of triamcinolone acetonide in atopic dermatitis. Int J Dermatol, 2001. 40(3): p. 232-6.
79. Wahn, U., et al., Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics, 2002. 110(1 Pt 1): p. e2.
80. Kaplan, R.J., et al., Topical use of caffeine with hydrocortisone in the treatment of atopic dermatitis. Arch Dermatol, 1978. 114(1): p. 60-2.
81. Chapman, R.S., Treatment of atopic dermatitis. Practitioner, 1979. 223(1337): p. 713-6.
82. Torok, H.M., R. Maas-Irslinger, and R.M. Slayton, Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis. Cutis, 2003. 72(2): p. 161-6.
83. Noren, P. and L. Melin, The effect of combined topical steroids and habit-reversal treatment in patients with atopic dermatitis. Br J Dermatol, 1989. 121(3): p. 359-66.
84. Luger, T., et al., SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol, 2001. 144(4): p. 788-94.
85. Griffiths, C.E., et al., Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. Br J Dermatol, 2002. 147(2): p. 299-307.
86. Munkvad, M., A comparative trial of Clinitar versus hydrocortisone cream in the treatment of atopic eczema. Br J Dermatol, 1989. 121(6): p. 763-6.
87. Hiratsuka, S., et al., Enhancement of in vitro spontaneous IgE production by topical steroids in patients with atopic dermatitis. J Allergy Clin Immunol, 1996. 98(1): p. 107-13.
88. Wolkerstorfer, A., et al., Efficacy and safety of wet-wrap dressings in children with severe atopic dermatitis: influence of corticosteroid dilution. Br J Dermatol, 2000. 143(5): p. 999-1004.
89. Pei, A.Y., H.H. Chan, and K.M. Ho, The effectiveness of wet wrap dressings using 0.1% mometasone furoate and 0.005% fluticasone proprionate ointments in the treatment of moderate to severe atopic dermatitis in children. Pediatr Dermatol, 2001. 18(4): p. 343-8.
90. Schnopp, C., et al., Topical steroids under wet-wrap dressings in atopic dermatitis--a vehicle-controlled trial. Dermatology, 2002. 204(1): p. 56-9.
91. Foelster-Holst, R., et al., Efficacy of crisis intervention treatment with topical corticosteroid prednicarbat with and without partial wet-wrap dressing in atopic dermatitis. Dermatology, 2006. 212(1): p. 66-9.
92. Hindley, D., et al., A randomised study of "wet wraps" versus conventional treatment for atopic eczema. Arch Dis Child, 2006. 91(2): p. 164-8.
93. Bleehen, S.S., et al., Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol, 1995. 133(4): p. 592-7.
94. Koopmans B, L.A.B., Mork NJ, Austad J, Suhonen RE., Multicentre randomized double-blind study of locoid lipocream fatty cream twice daily versus locoid lipocream once daily and loco-base once daily. J Dermatol Treat., 1995. 6(2): p. 103-106.
95. Hoare, C., A. Li Wan Po, and H. Williams, Systematic review of treatments for atopic eczema. Health Technol Assess, 2000. 4(37): p. 1-191.
96. Berth-Jones, J., et al., Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ, 2003. 326(7403): p. 1367.
97. Peserico, A., et al., Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol, 2008. 158(4): p. 801-7.
98. Glazenburg, E.J., et al., Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? Pediatr Allergy Immunol, 2009. 20(1): p. 59-66.
99. Kirkup, M.E., et al., Acute and maintenance treatment of atopic dermatitis in children - two comparative studies with fluticasone propionate (0.05%) cream. J Dermatolog Treat, 2003. 14(3): p. 141-8.
100. Thomas, K.S., et al., Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ, 2002. 324(7340): p. 768.
101. Faergemann, J., et al., An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol, 2000. 14(5): p. 393-6.
102. Hanifin, J., A.K. Gupta, and R. Rajagopalan, Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol, 2002. 147(3): p. 528-37.
103. Korting, H.C., et al., Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol Appl Skin Physiol, 2002. 15(2): p. 85-91.
104. Kerscher, M.J., et al., In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther, 1995. 33(4): p. 187-9.
105. Kerscher, M.J. and H.C. Korting, Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound. Acta Derm Venereol, 1992. 72(3): p. 214-6.
106. Korting, H.C., D. Vieluf, and M. Kerscher, 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. Eur J Clin Pharmacol, 1992. 42(2): p. 159-61.
107. Kerscher, M.J., et al., 0.05% clobetasol 17-propionate cream and ointment but not the corresponding 0.1% triamcinolone acetonide preparations increase skin surface roughness: a possible dissociation of unwanted epidermal and dermal effects. Skin Pharmacol, 1996. 9(2): p. 120-3.
108. Furue, M., et al., Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol, 2003. 148(1): p. 128-33.
109. Corazza, M., et al., Contact sensitization to corticosteroids: increased risk in long term dermatoses. Eur J Dermatol, 2000. 10(7): p. 533-5.
110. Matsuda, K., et al., Adrenocortical function in patients with severe atopic dermatitis. Ann Allergy Asthma Immunol, 2000. 85(1): p. 35-9.
111. Hida, T., et al., Multicenter retrospective study of retinal detachment associated with atopic dermatitis. Jpn J Ophthalmol, 2000. 44(4): p. 407-18.
112. Ellison, J.A., et al., Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics, 2000. 105(4 Pt 1): p. 794-9.
113. Eichenfield, L.F., et al., Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis. Pediatr Dermatol, 2007. 24(3): p. 289-95.
114. Friedlander, S.F., A.A. Hebert, and D.B. Allen, Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol, 2002. 46(3): p. 387-93.
115. Hebert, A.A., S.F. Friedlander, and D.B. Allen, Topical fluticasone propionate lotion does not cause HPA axis suppression. J Pediatr, 2006. 149(3): p. 378-82.
116. Patel, L., et al., Adrenal function following topical steroid treatment in children with atopic dermatitis. Br J Dermatol, 1995. 132(6): p. 950-5.
117. Schlessinger, J., et al., An open-label adrenal suppression study of 0.1% fluocinonide cream in pediatric patients with atopic dermatitis. Arch Dermatol, 2006. 142(12): p. 1568-72.
118. Long, C.C. and A.Y. Finlay, The finger-tip unit--a new practical measure. Clin Exp Dermatol, 1991. 16(6): p. 444-7.
119. Long, C.C., C.M. Mills, and A.Y. Finlay, A practical guide to topical therapy in children. Br J Dermatol, 1998. 138(2): p. 293-6.
ƒgƒbƒvƒy[ƒW‚Ö–ß‚é ã‚Ö–ß‚é
‹ãB‘åŠwˆãŠw•””畆‰ÈŠw‹³ŽºTOP‚Ö